Your browser doesn't support javascript.
loading
Hyperprogression during immunotherapy: do we really want to know?
Champiat, S; Besse, B; Marabelle, A.
Affiliation
  • Champiat S; Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif; Medical School, Paris-Saclay University, Paris-Sud University, Le Kremlin Bicêtre; UMR8200 - CNRS. Electronic address: stephane.champiat@gustaveroussy.fr.
  • Besse B; Medical Oncology Department, Gustave Roussy.
  • Marabelle A; Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif; INSERM, U1015, Paris-Saclay University, Villejuif, France.
Ann Oncol ; 30(7): 1028-1031, 2019 07 01.
Article in En | MEDLINE | ID: mdl-31173063
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: